Improving Regulatory Transparency for New Medical Therapies Actby Representative Gene Green
Posted on 2015-03-16
GREEN of Texas. Mr. Speaker, I yield myself as much time as
I may consume.
Mr. Speaker, I rise in support of H.R. 639, the Improving Regulatory Transparency for New Medical Therapies Act. This legislation was introduced by the chair of our Health Subcommittee, Joe Pitts of Pennsylvania; the ranking member of the full committee, Frank Pallone of New Jersey; and myself to provide a solution to delays experienced by patients in need.
Currently, new drugs and substances that previously have not been marketed in the United States and that have abuse potential must be scheduled by the Drug Enforcement Administration prior to being marketed.
The amount of time the DEA has taken before acting on FDA recommendations has significantly lengthened in recent years, which delays the availability of new therapies.
This legislation will improve patient access by bringing clarity and transparency to the process of scheduling a new FDA-approved therapy.
I was pleased to join the gentleman from Pennsylvania (Mr. Pitts) and the gentleman from New Jersey (Mr. Pallone) in supporting this legislation to continue the great work they started last Congress. I thank them and their staff for working on this important access issue.
I want to acknowledge the leadership of Chairman Upton and the work of the committee's minority and majority staff in advancing this bill through the Energy and Commerce Committee. I [[Page H1641]] support this bipartisan bill and urge my colleagues to do the same.
Mr. Speaker, I yield back the balance of my time.